Kathryn Horwitz
Concepts (514)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Progesterone | 112 | 2020 | 356 | 9.650 |
Why?
| | Breast Neoplasms | 119 | 2021 | 2447 | 5.580 |
Why?
| | Progesterone | 47 | 2021 | 255 | 4.800 |
Why?
| | Receptors, Estrogen | 57 | 2014 | 457 | 3.620 |
Why?
| | Progestins | 23 | 2021 | 87 | 2.570 |
Why?
| | Estrogens | 17 | 2014 | 380 | 1.840 |
Why?
| | Gene Expression Regulation, Neoplastic | 21 | 2015 | 1455 | 1.710 |
Why?
| | Tamoxifen | 26 | 2012 | 217 | 1.600 |
Why?
| | Transcription, Genetic | 29 | 2012 | 1495 | 1.520 |
Why?
| | Estradiol | 28 | 2014 | 533 | 1.490 |
Why?
| | SUMO-1 Protein | 4 | 2012 | 22 | 0.900 |
Why?
| | Tumor Cells, Cultured | 32 | 2009 | 919 | 0.730 |
Why?
| | Keratin-5 | 4 | 2014 | 48 | 0.690 |
Why?
| | Gene Expression Profiling | 13 | 2014 | 1782 | 0.690 |
Why?
| | Neoplasms, Hormone-Dependent | 8 | 2010 | 41 | 0.650 |
Why?
| | Promegestone | 24 | 2005 | 33 | 0.630 |
Why?
| | Transcription Factors | 12 | 2009 | 1739 | 0.600 |
Why?
| | Gene Expression Regulation | 10 | 2011 | 2603 | 0.590 |
Why?
| | Cell Proliferation | 9 | 2014 | 2494 | 0.570 |
Why?
| | Stromal Cells | 5 | 2014 | 124 | 0.570 |
Why?
| | Biomarkers, Tumor | 8 | 2020 | 1313 | 0.560 |
Why?
| | HeLa Cells | 15 | 2012 | 650 | 0.530 |
Why?
| | Protein Processing, Post-Translational | 4 | 2013 | 477 | 0.520 |
Why?
| | Estrogen Replacement Therapy | 2 | 2008 | 143 | 0.520 |
Why?
| | Promoter Regions, Genetic | 12 | 2012 | 1255 | 0.520 |
Why?
| | Humans | 157 | 2021 | 144261 | 0.490 |
Why?
| | Female | 106 | 2021 | 77976 | 0.490 |
Why?
| | Cell Line, Tumor | 19 | 2014 | 3539 | 0.480 |
Why?
| | Medroxyprogesterone Acetate | 3 | 2005 | 37 | 0.480 |
Why?
| | Neovascularization, Pathologic | 2 | 2014 | 286 | 0.450 |
Why?
| | Cell Nucleus | 27 | 2008 | 618 | 0.450 |
Why?
| | Mifepristone | 11 | 2000 | 64 | 0.450 |
Why?
| | Neoplastic Stem Cells | 3 | 2008 | 412 | 0.440 |
Why?
| | Down-Regulation | 9 | 2009 | 627 | 0.440 |
Why?
| | Phosphorylation | 19 | 2013 | 1732 | 0.430 |
Why?
| | Antineoplastic Agents, Hormonal | 6 | 2010 | 194 | 0.430 |
Why?
| | Lymphatic Metastasis | 4 | 2010 | 333 | 0.430 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2014 | 90 | 0.430 |
Why?
| | Molecular Sequence Data | 21 | 2009 | 2929 | 0.430 |
Why?
| | Histone Acetyltransferases | 4 | 2012 | 62 | 0.420 |
Why?
| | Epigenomics | 1 | 2015 | 114 | 0.420 |
Why?
| | Animals | 54 | 2014 | 38030 | 0.420 |
Why?
| | Epidermal Growth Factor | 8 | 2005 | 171 | 0.410 |
Why?
| | Mice | 27 | 2014 | 18329 | 0.410 |
Why?
| | Transcriptional Activation | 9 | 2009 | 382 | 0.410 |
Why?
| | Epithelium | 3 | 2013 | 314 | 0.390 |
Why?
| | Mice, Nude | 9 | 2012 | 682 | 0.390 |
Why?
| | Cell Division | 12 | 2003 | 766 | 0.370 |
Why?
| | Cell Line | 35 | 2009 | 2879 | 0.360 |
Why?
| | Protein Isoforms | 6 | 2011 | 402 | 0.360 |
Why?
| | MCF-7 Cells | 4 | 2020 | 135 | 0.350 |
Why?
| | Binding Sites | 15 | 2006 | 1327 | 0.350 |
Why?
| | Enzyme Inhibitors | 3 | 2008 | 824 | 0.350 |
Why?
| | DNA-Binding Proteins | 10 | 2000 | 1497 | 0.350 |
Why?
| | Repressor Proteins | 5 | 2002 | 437 | 0.340 |
Why?
| | Signal Transduction | 18 | 2012 | 5221 | 0.340 |
Why?
| | Cyclins | 4 | 1999 | 84 | 0.340 |
Why?
| | Neoplasm Proteins | 4 | 2005 | 442 | 0.340 |
Why?
| | Models, Biological | 5 | 2014 | 1820 | 0.330 |
Why?
| | DNA | 11 | 2000 | 1460 | 0.330 |
Why?
| | Receptors, Notch | 1 | 2011 | 92 | 0.330 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2010 | 9 | 0.320 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 684 | 0.310 |
Why?
| | Peritoneal Neoplasms | 1 | 2010 | 103 | 0.310 |
Why?
| | DNA Methylation | 1 | 2015 | 681 | 0.300 |
Why?
| | Transplantation, Heterologous | 6 | 2009 | 193 | 0.300 |
Why?
| | Adenocarcinoma | 2 | 2014 | 927 | 0.300 |
Why?
| | Nuclear Proteins | 7 | 2000 | 748 | 0.300 |
Why?
| | Alu Elements | 1 | 2009 | 28 | 0.290 |
Why?
| | Milk Proteins | 2 | 1999 | 35 | 0.290 |
Why?
| | Neoplasm Transplantation | 4 | 2014 | 251 | 0.280 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 688 | 0.280 |
Why?
| | Amino Acid Sequence | 12 | 2009 | 2154 | 0.270 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2010 | 881 | 0.270 |
Why?
| | Nuclear Receptor Coactivator 1 | 4 | 2012 | 10 | 0.270 |
Why?
| | Protein Multimerization | 1 | 2009 | 213 | 0.270 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 75 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2013 | 1137 | 0.260 |
Why?
| | Cyclic AMP | 5 | 2006 | 208 | 0.260 |
Why?
| | Cysteine Endopeptidases | 3 | 2012 | 73 | 0.260 |
Why?
| | Ligands | 10 | 2009 | 673 | 0.250 |
Why?
| | Saccharomyces cerevisiae Proteins | 2 | 2001 | 418 | 0.250 |
Why?
| | Cell Fusion | 1 | 2006 | 49 | 0.250 |
Why?
| | Breast | 5 | 2001 | 157 | 0.240 |
Why?
| | Models, Theoretical | 2 | 2008 | 582 | 0.230 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2010 | 36 | 0.230 |
Why?
| | Trans-Activators | 5 | 1999 | 405 | 0.230 |
Why?
| | Base Sequence | 11 | 2009 | 2187 | 0.220 |
Why?
| | DNA, Neoplasm | 6 | 1992 | 163 | 0.210 |
Why?
| | Protein Binding | 10 | 2009 | 2270 | 0.210 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 586 | 0.210 |
Why?
| | Epithelial Cells | 2 | 2010 | 1125 | 0.200 |
Why?
| | RNA, Messenger | 11 | 2010 | 2829 | 0.200 |
Why?
| | Gonanes | 5 | 1997 | 28 | 0.200 |
Why?
| | Drug Resistance | 8 | 2000 | 153 | 0.200 |
Why?
| | Lymph Nodes | 1 | 2006 | 502 | 0.200 |
Why?
| | Cell Growth Processes | 3 | 2010 | 50 | 0.200 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.200 |
Why?
| | Receptors, Steroid | 4 | 1999 | 45 | 0.200 |
Why?
| | Sumoylation | 2 | 2013 | 18 | 0.190 |
Why?
| | Molecular Weight | 11 | 2000 | 327 | 0.190 |
Why?
| | Peptide Fragments | 5 | 2003 | 698 | 0.190 |
Why?
| | Mutation | 7 | 2012 | 4085 | 0.190 |
Why?
| | Receptors, Cell Surface | 7 | 1994 | 377 | 0.190 |
Why?
| | ErbB Receptors | 4 | 2020 | 627 | 0.190 |
Why?
| | Disease Models, Animal | 4 | 2014 | 4556 | 0.180 |
Why?
| | Phosphoserine | 2 | 2000 | 27 | 0.180 |
Why?
| | Norpregnadienes | 3 | 1988 | 6 | 0.180 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 167 | 0.170 |
Why?
| | Immunohistochemistry | 6 | 2008 | 1715 | 0.170 |
Why?
| | Leucine Zippers | 3 | 1997 | 17 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2012 | 928 | 0.170 |
Why?
| | Transfection | 8 | 2006 | 938 | 0.170 |
Why?
| | Multienzyme Complexes | 2 | 2003 | 67 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2000 | 292 | 0.160 |
Why?
| | Antibodies, Monoclonal | 9 | 2006 | 1519 | 0.160 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.160 |
Why?
| | Recombinant Fusion Proteins | 6 | 2000 | 674 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 981 | 0.160 |
Why?
| | Homeodomain Proteins | 3 | 2009 | 523 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 86 | 0.150 |
Why?
| | Estrogen Antagonists | 11 | 2000 | 48 | 0.150 |
Why?
| | Response Elements | 3 | 2009 | 89 | 0.150 |
Why?
| | Prolactin | 2 | 1998 | 89 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 346 | 0.150 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.140 |
Why?
| | Kinetics | 15 | 2001 | 1627 | 0.140 |
Why?
| | Amino Acid Motifs | 3 | 2006 | 224 | 0.140 |
Why?
| | MAP Kinase Signaling System | 2 | 2001 | 309 | 0.140 |
Why?
| | Hormone Antagonists | 2 | 1997 | 34 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 2 | 1998 | 321 | 0.140 |
Why?
| | DNA Helicases | 1 | 2000 | 143 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 862 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2020 | 229 | 0.140 |
Why?
| | Risk | 1 | 2021 | 909 | 0.140 |
Why?
| | Progesterone Congeners | 5 | 2008 | 14 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-fos | 2 | 1998 | 196 | 0.140 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 4 | 1999 | 112 | 0.140 |
Why?
| | Affinity Labels | 9 | 1990 | 25 | 0.140 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2010 | 758 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 128 | 0.130 |
Why?
| | Oxygenases | 1 | 1997 | 13 | 0.130 |
Why?
| | CDC2-CDC28 Kinases | 1 | 1997 | 17 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 5 | 2001 | 381 | 0.130 |
Why?
| | Nafoxidine | 8 | 1982 | 9 | 0.130 |
Why?
| | Endometrium | 2 | 2008 | 61 | 0.130 |
Why?
| | Immunoblotting | 4 | 2004 | 300 | 0.130 |
Why?
| | Phosphoproteins | 3 | 2008 | 343 | 0.130 |
Why?
| | Endopeptidases | 2 | 2012 | 82 | 0.130 |
Why?
| | Hyaluronan Receptors | 2 | 2008 | 102 | 0.130 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 2 | 1994 | 20 | 0.130 |
Why?
| | Endometrial Neoplasms | 4 | 2008 | 208 | 0.130 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 91 | 0.130 |
Why?
| | Carcinogens | 1 | 1997 | 122 | 0.130 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 51 | 0.130 |
Why?
| | Cytoplasm | 12 | 2006 | 269 | 0.130 |
Why?
| | Up-Regulation | 3 | 2009 | 851 | 0.120 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2000 | 452 | 0.120 |
Why?
| | Cluster Analysis | 4 | 2008 | 519 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 1 | 1997 | 196 | 0.120 |
Why?
| | Apoptosis | 5 | 2011 | 2430 | 0.120 |
Why?
| | Blotting, Western | 6 | 2010 | 1187 | 0.120 |
Why?
| | Mammary Neoplasms, Experimental | 8 | 2009 | 70 | 0.120 |
Why?
| | Receptors, Glucocorticoid | 8 | 2000 | 138 | 0.110 |
Why?
| | Consensus Sequence | 2 | 2009 | 74 | 0.110 |
Why?
| | Phenotype | 5 | 2011 | 3157 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1996 | 209 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 1994 | 55 | 0.110 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 732 | 0.110 |
Why?
| | Methylation | 1 | 2015 | 242 | 0.110 |
Why?
| | Heterografts | 1 | 2014 | 143 | 0.100 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 108 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2014 | 191 | 0.100 |
Why?
| | Estrenes | 4 | 1989 | 17 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 1997 | 628 | 0.100 |
Why?
| | Immunoenzyme Techniques | 2 | 2010 | 200 | 0.100 |
Why?
| | Ubiquitination | 1 | 2013 | 118 | 0.100 |
Why?
| | Small Molecule Libraries | 1 | 2014 | 110 | 0.100 |
Why?
| | Fibroblasts | 2 | 2020 | 1032 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2006 | 459 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 322 | 0.100 |
Why?
| | Drug Synergism | 4 | 1998 | 357 | 0.100 |
Why?
| | Acetylation | 1 | 2013 | 252 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 28 | 0.090 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2013 | 63 | 0.090 |
Why?
| | Chickens | 6 | 1994 | 191 | 0.090 |
Why?
| | DNA, Complementary | 4 | 2001 | 276 | 0.090 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 56 | 0.090 |
Why?
| | Bone Neoplasms | 1 | 2014 | 253 | 0.090 |
Why?
| | Claudins | 1 | 2011 | 23 | 0.090 |
Why?
| | Disease Progression | 3 | 2014 | 2840 | 0.090 |
Why?
| | Cells, Cultured | 10 | 2006 | 4146 | 0.090 |
Why?
| | Cytosol | 9 | 1989 | 227 | 0.090 |
Why?
| | Bridged-Ring Compounds | 1 | 2011 | 31 | 0.080 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 24 | 0.080 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2011 | 77 | 0.080 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 14 | 0.080 |
Why?
| | Polyploidy | 1 | 1990 | 15 | 0.080 |
Why?
| | Neoplasms, Experimental | 4 | 2008 | 173 | 0.080 |
Why?
| | Taxoids | 1 | 2011 | 116 | 0.080 |
Why?
| | Acetylcysteine | 2 | 2003 | 138 | 0.080 |
Why?
| | Receptor, Insulin | 3 | 1985 | 94 | 0.080 |
Why?
| | Genome, Human | 1 | 2013 | 422 | 0.080 |
Why?
| | Pyrrolidines | 3 | 1981 | 125 | 0.080 |
Why?
| | Estrogen Receptor alpha | 2 | 2010 | 161 | 0.080 |
Why?
| | COS Cells | 2 | 2003 | 181 | 0.080 |
Why?
| | Hormones | 2 | 1993 | 134 | 0.080 |
Why?
| | Cloning, Molecular | 4 | 2006 | 539 | 0.080 |
Why?
| | Organ Specificity | 1 | 2010 | 312 | 0.080 |
Why?
| | Chemokine CXCL12 | 1 | 2010 | 89 | 0.080 |
Why?
| | Epitopes | 1 | 1991 | 485 | 0.070 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 13 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 2192 | 0.070 |
Why?
| | Histones | 1 | 2015 | 668 | 0.070 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2009 | 157 | 0.070 |
Why?
| | Receptors, Androgen | 5 | 2005 | 153 | 0.070 |
Why?
| | Transformation, Genetic | 1 | 1988 | 15 | 0.070 |
Why?
| | STAT5 Transcription Factor | 2 | 1999 | 52 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2000 | 138 | 0.070 |
Why?
| | Time Factors | 4 | 2008 | 7155 | 0.070 |
Why?
| | Drug Administration Routes | 1 | 2008 | 42 | 0.070 |
Why?
| | Embryonal Carcinoma Stem Cells | 1 | 2008 | 2 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2000 | 175 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2010 | 462 | 0.070 |
Why?
| | Protein Precursors | 1 | 1989 | 136 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 700 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 388 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2014 | 780 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 76 | 0.070 |
Why?
| | Microdissection | 1 | 2007 | 15 | 0.070 |
Why?
| | Mammary Tumor Virus, Mouse | 2 | 2000 | 45 | 0.070 |
Why?
| | Transcriptome | 1 | 2014 | 1044 | 0.070 |
Why?
| | Dactinomycin | 4 | 1981 | 27 | 0.070 |
Why?
| | Binding, Competitive | 6 | 1994 | 193 | 0.070 |
Why?
| | Pregnanes | 1 | 1986 | 3 | 0.060 |
Why?
| | Lasers | 1 | 2007 | 132 | 0.060 |
Why?
| | Structure-Activity Relationship | 2 | 2002 | 567 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 479 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 2003 | 1367 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 64 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 778 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 508 | 0.060 |
Why?
| | Pregnanolone | 1 | 1986 | 35 | 0.060 |
Why?
| | Menopause | 3 | 2008 | 319 | 0.060 |
Why?
| | Mutant Proteins | 1 | 2006 | 106 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2005 | 2026 | 0.060 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2006 | 47 | 0.060 |
Why?
| | Cell Cycle | 2 | 1999 | 596 | 0.060 |
Why?
| | Pleural Effusion | 1 | 2006 | 60 | 0.060 |
Why?
| | Zinc Fingers | 2 | 1998 | 53 | 0.060 |
Why?
| | Protein Biosynthesis | 3 | 2000 | 458 | 0.060 |
Why?
| | Chromatography, Affinity | 4 | 1990 | 85 | 0.060 |
Why?
| | Methionine | 2 | 2000 | 162 | 0.060 |
Why?
| | Regulatory Sequences, Nucleic Acid | 3 | 1997 | 96 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 369 | 0.060 |
Why?
| | Chromosome Mapping | 4 | 1999 | 509 | 0.060 |
Why?
| | Hydroxyprogesterones | 1 | 1985 | 1 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2014 | 1318 | 0.060 |
Why?
| | Uterine Neoplasms | 1 | 2006 | 96 | 0.060 |
Why?
| | Keratins | 1 | 2005 | 172 | 0.060 |
Why?
| | Gene Regulatory Networks | 1 | 2007 | 318 | 0.060 |
Why?
| | Thromboplastin | 1 | 2004 | 69 | 0.050 |
Why?
| | Cycloheximide | 4 | 1989 | 46 | 0.050 |
Why?
| | Chloramphenicol O-Acetyltransferase | 2 | 1994 | 36 | 0.050 |
Why?
| | Dexamethasone | 5 | 2000 | 370 | 0.050 |
Why?
| | Dimerization | 2 | 2002 | 193 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2006 | 339 | 0.050 |
Why?
| | Protein Conformation | 2 | 2001 | 946 | 0.050 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 321 | 0.050 |
Why?
| | Cell Movement | 2 | 2006 | 965 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2005 | 169 | 0.050 |
Why?
| | Paclitaxel | 1 | 2004 | 255 | 0.050 |
Why?
| | Genes, Reporter | 2 | 1994 | 275 | 0.050 |
Why?
| | Plasmids | 2 | 2002 | 379 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2004 | 454 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4254 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2005 | 1304 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2003 | 159 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 366 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 396 | 0.050 |
Why?
| | Mutagenesis | 1 | 2003 | 190 | 0.050 |
Why?
| | Oligodeoxyribonucleotides | 2 | 1993 | 141 | 0.050 |
Why?
| | Flow Cytometry | 3 | 1992 | 1172 | 0.040 |
Why?
| | Biomedical Research | 1 | 2008 | 709 | 0.040 |
Why?
| | Uterus | 1 | 2003 | 226 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2001 | 18 | 0.040 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 2001 | 19 | 0.040 |
Why?
| | Oligonucleotide Probes | 2 | 1992 | 50 | 0.040 |
Why?
| | Growth Substances | 2 | 1999 | 140 | 0.040 |
Why?
| | Testosterone | 1 | 2005 | 419 | 0.040 |
Why?
| | Androgens | 7 | 1986 | 186 | 0.040 |
Why?
| | Oviducts | 3 | 1986 | 16 | 0.040 |
Why?
| | Ultracentrifugation | 1 | 2001 | 51 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2637 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 557 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2006 | 2048 | 0.040 |
Why?
| | Gene Library | 2 | 1992 | 126 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2001 | 193 | 0.040 |
Why?
| | Pregnancy | 2 | 2013 | 7180 | 0.040 |
Why?
| | Genetic Variation | 2 | 1999 | 982 | 0.040 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2000 | 38 | 0.040 |
Why?
| | Ku Autoantigen | 1 | 2000 | 12 | 0.040 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 15 | 0.040 |
Why?
| | Exons | 2 | 1999 | 358 | 0.040 |
Why?
| | CD146 Antigen | 1 | 2020 | 40 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2000 | 100 | 0.040 |
Why?
| | Ubiquitins | 1 | 2000 | 33 | 0.040 |
Why?
| | Peptides, Cyclic | 1 | 2001 | 275 | 0.040 |
Why?
| | Phosphates | 2 | 1993 | 179 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Nucleic Acid Hybridization | 2 | 1990 | 187 | 0.040 |
Why?
| | Phosphotyrosine | 1 | 1998 | 39 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 56 | 0.040 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 1998 | 46 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 68 | 0.040 |
Why?
| | Protein Folding | 1 | 2000 | 279 | 0.040 |
Why?
| | Imidazoles | 1 | 2000 | 254 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 153 | 0.030 |
Why?
| | Immunoassay | 2 | 1989 | 109 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 25 | 0.030 |
Why?
| | Suppression, Genetic | 1 | 1998 | 24 | 0.030 |
Why?
| | Hydrocortisone | 3 | 1985 | 304 | 0.030 |
Why?
| | Cyclin B | 1 | 1997 | 16 | 0.030 |
Why?
| | Glycoproteins | 1 | 2000 | 355 | 0.030 |
Why?
| | Cyclin A | 1 | 1997 | 18 | 0.030 |
Why?
| | Dihydrotestosterone | 3 | 1979 | 42 | 0.030 |
Why?
| | Rats | 9 | 1991 | 5592 | 0.030 |
Why?
| | Isomerism | 1 | 1997 | 57 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 266 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1997 | 66 | 0.030 |
Why?
| | Cell Compartmentation | 3 | 1989 | 54 | 0.030 |
Why?
| | G1 Phase | 1 | 1997 | 66 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1997 | 73 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 412 | 0.030 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 2 | 2008 | 23 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 1997 | 36 | 0.030 |
Why?
| | Middle Aged | 6 | 2013 | 35762 | 0.030 |
Why?
| | Yeasts | 1 | 1997 | 52 | 0.030 |
Why?
| | Autoantigens | 1 | 2000 | 429 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 207 | 0.030 |
Why?
| | Blood Platelets | 2 | 1994 | 399 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1986 | 131 | 0.030 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1997 | 123 | 0.030 |
Why?
| | Photochemistry | 2 | 1990 | 133 | 0.030 |
Why?
| | Gene Expression | 3 | 2006 | 1487 | 0.030 |
Why?
| | Chromatin | 1 | 2000 | 561 | 0.030 |
Why?
| | Centrifugation, Density Gradient | 4 | 1983 | 40 | 0.030 |
Why?
| | Pyridines | 1 | 2000 | 605 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2000 | 93 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2001 | 1165 | 0.030 |
Why?
| | Molecular Structure | 1 | 1996 | 498 | 0.030 |
Why?
| | Protein Kinases | 2 | 2008 | 315 | 0.030 |
Why?
| | TATA Box | 1 | 1994 | 22 | 0.030 |
Why?
| | Adult | 5 | 2013 | 40262 | 0.030 |
Why?
| | Biopolymers | 1 | 1994 | 34 | 0.030 |
Why?
| | Prognosis | 4 | 2009 | 4278 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 1994 | 84 | 0.030 |
Why?
| | Estradiol Congeners | 3 | 1981 | 3 | 0.030 |
Why?
| | Chromatography, DEAE-Cellulose | 2 | 1985 | 12 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 10699 | 0.030 |
Why?
| | Glucocorticoids | 6 | 2000 | 533 | 0.030 |
Why?
| | Genes, jun | 1 | 1993 | 10 | 0.030 |
Why?
| | Genes, fos | 1 | 1993 | 37 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1995 | 1047 | 0.020 |
Why?
| | Antibodies | 2 | 1986 | 401 | 0.020 |
Why?
| | Aneuploidy | 1 | 1994 | 90 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 1993 | 77 | 0.020 |
Why?
| | Macromolecular Substances | 2 | 1983 | 224 | 0.020 |
Why?
| | Karyotyping | 1 | 2012 | 106 | 0.020 |
Why?
| | Serotonin | 1 | 1994 | 293 | 0.020 |
Why?
| | Castration | 4 | 1982 | 15 | 0.020 |
Why?
| | Reference Values | 1 | 1994 | 797 | 0.020 |
Why?
| | Ploidies | 1 | 1992 | 20 | 0.020 |
Why?
| | Ultraviolet Rays | 2 | 1985 | 387 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 2 | 1985 | 25 | 0.020 |
Why?
| | Clone Cells | 1 | 1992 | 266 | 0.020 |
Why?
| | Serine | 2 | 2003 | 145 | 0.020 |
Why?
| | Cytokines | 1 | 1999 | 2061 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 59 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 99 | 0.020 |
Why?
| | Codon | 1 | 1990 | 94 | 0.020 |
Why?
| | Rabbits | 1 | 1991 | 648 | 0.020 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1990 | 45 | 0.020 |
Why?
| | Radioligand Assay | 1 | 1989 | 37 | 0.020 |
Why?
| | Acceleration | 1 | 1969 | 33 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 199 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2009 | 43 | 0.020 |
Why?
| | Estrogen Receptor beta | 2 | 2000 | 43 | 0.020 |
Why?
| | Cyanogen Bromide | 1 | 1989 | 1 | 0.020 |
Why?
| | Peptide Mapping | 1 | 1989 | 63 | 0.020 |
Why?
| | Formaldehyde | 1 | 1989 | 66 | 0.020 |
Why?
| | Trypsin | 1 | 1989 | 76 | 0.020 |
Why?
| | Neoplasms | 1 | 2004 | 2870 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1987 | 72 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 369 | 0.020 |
Why?
| | Endometrial Hyperplasia | 1 | 2008 | 7 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1989 | 370 | 0.020 |
Why?
| | Mesoderm | 1 | 2009 | 150 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2008 | 50 | 0.020 |
Why?
| | Testosterone Congeners | 2 | 1979 | 9 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 286 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 36 | 0.020 |
Why?
| | Phosphorus Radioisotopes | 1 | 1987 | 26 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 610 | 0.020 |
Why?
| | DNA Primers | 2 | 1998 | 511 | 0.020 |
Why?
| | Hysterectomy | 1 | 2008 | 137 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 205 | 0.020 |
Why?
| | 3-Hydroxysteroid Dehydrogenases | 1 | 1986 | 9 | 0.020 |
Why?
| | Steroid Hydroxylases | 1 | 1986 | 20 | 0.020 |
Why?
| | Protein C Inhibitor | 1 | 2006 | 1 | 0.020 |
Why?
| | Chromatography, Thin Layer | 1 | 1986 | 27 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 593 | 0.020 |
Why?
| | Chromatography, Gas | 1 | 1986 | 32 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 55 | 0.020 |
Why?
| | Ligases | 1 | 2006 | 37 | 0.020 |
Why?
| | Cadherins | 1 | 2008 | 200 | 0.020 |
Why?
| | Half-Life | 1 | 1986 | 151 | 0.020 |
Why?
| | Heterotrimeric GTP-Binding Proteins | 1 | 2006 | 12 | 0.020 |
Why?
| | RNA | 2 | 2005 | 939 | 0.010 |
Why?
| | Stress, Physiological | 1 | 1969 | 453 | 0.010 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2006 | 26 | 0.010 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2006 | 44 | 0.010 |
Why?
| | Androstenes | 1 | 2005 | 17 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2005 | 35 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 330 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1998 | 1054 | 0.010 |
Why?
| | Polymers | 1 | 1989 | 498 | 0.010 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 1985 | 3 | 0.010 |
Why?
| | Cell Fractionation | 2 | 1982 | 52 | 0.010 |
Why?
| | Cricetinae | 2 | 1999 | 303 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 143 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 476 | 0.010 |
Why?
| | Amino Acids | 1 | 1988 | 521 | 0.010 |
Why?
| | Calcitriol | 1 | 1985 | 58 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1985 | 61 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 319 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 112 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2004 | 101 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 649 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 2006 | 199 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1461 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 148 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1986 | 629 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 736 | 0.010 |
Why?
| | Homeostasis | 1 | 1988 | 640 | 0.010 |
Why?
| | Aged | 3 | 2012 | 25850 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1983 | 129 | 0.010 |
Why?
| | Butadienes | 1 | 2003 | 37 | 0.010 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2003 | 50 | 0.010 |
Why?
| | Lymphocytes | 1 | 1985 | 382 | 0.010 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2003 | 121 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2003 | 97 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2004 | 768 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1982 | 79 | 0.010 |
Why?
| | Hypophysectomy | 3 | 1977 | 15 | 0.010 |
Why?
| | Nitriles | 1 | 2003 | 205 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2004 | 634 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1098 | 0.010 |
Why?
| | Butyrates | 1 | 1982 | 67 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 1985 | 525 | 0.010 |
Why?
| | Deoxyadenosines | 1 | 1980 | 8 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 437 | 0.010 |
Why?
| | Y-Box-Binding Protein 1 | 1 | 2000 | 6 | 0.010 |
Why?
| | NFI Transcription Factors | 1 | 2000 | 8 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2004 | 1322 | 0.010 |
Why?
| | Diethylstilbestrol | 2 | 1979 | 9 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 1984 | 1050 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 67 | 0.010 |
Why?
| | Aorta | 1 | 1982 | 429 | 0.010 |
Why?
| | Coumestrol | 1 | 1978 | 1 | 0.010 |
Why?
| | Mycotoxins | 1 | 1978 | 4 | 0.010 |
Why?
| | Coumarins | 1 | 1978 | 17 | 0.010 |
Why?
| | Isoflavones | 1 | 1978 | 26 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 123 | 0.010 |
Why?
| | Subcellular Fractions | 1 | 1978 | 74 | 0.010 |
Why?
| | Flavonoids | 1 | 1978 | 87 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 387 | 0.010 |
Why?
| | Insulin | 1 | 1988 | 2501 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 322 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 998 | 0.010 |
Why?
| | Remission, Spontaneous | 1 | 1977 | 40 | 0.010 |
Why?
| | Hypersensitivity | 1 | 2000 | 252 | 0.010 |
Why?
| | Recurrence | 2 | 1978 | 1134 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1977 | 77 | 0.010 |
Why?
| | Postmenopause | 1 | 1999 | 391 | 0.010 |
Why?
| | Sex Factors | 1 | 1982 | 2096 | 0.010 |
Why?
| | Fluoxymesterone | 1 | 1975 | 2 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2008 | 8243 | 0.010 |
Why?
| | Ovary | 1 | 1977 | 228 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5988 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1984 | 1953 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1997 | 724 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 999 | 0.010 |
Why?
| | Clostridium tetani | 1 | 1969 | 1 | 0.000 |
Why?
| | Nystagmus, Pathologic | 1 | 1969 | 20 | 0.000 |
Why?
| | Treatment Outcome | 1 | 2004 | 11643 | 0.000 |
Why?
| | Genetic Vectors | 1 | 1990 | 337 | 0.000 |
Why?
| | Peptides | 1 | 1994 | 995 | 0.000 |
Why?
| | Corticosterone | 1 | 1969 | 244 | 0.000 |
Why?
| | Salmonella typhimurium | 1 | 1969 | 190 | 0.000 |
Why?
| | Hybridomas | 1 | 1987 | 234 | 0.000 |
Why?
| | Adrenalectomy | 2 | 1977 | 71 | 0.000 |
Why?
| | Male | 3 | 1999 | 72035 | 0.000 |
Why?
| | Pindolol | 1 | 1985 | 3 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1987 | 1253 | 0.000 |
Why?
| | Blood Proteins | 1 | 1985 | 249 | 0.000 |
Why?
| | Solubility | 1 | 1980 | 242 | 0.000 |
Why?
| | Zeranol | 1 | 1978 | 1 | 0.000 |
Why?
| | Zearalenone | 1 | 1978 | 2 | 0.000 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1978 | 51 | 0.000 |
Why?
| | Aminoglutethimide | 1 | 1977 | 5 | 0.000 |
Why?
| | Species Specificity | 1 | 1976 | 574 | 0.000 |
Why?
|
|
Horwitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|